BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Saturday, March 21, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Aug. 9, 2016
View Archived Issues
Phase III trial to establish biosimilarity of SB8 to bevacizumab
Read More
Sarepta Therapeutics initiates phase III trial of SRP-4045 and SRP-4053 for the treatment of DMD
Read More
FDA grants emergency use authorization for Zika virus molecular detection assay
Read More
GVK Biosciences patents TrKA inhibitors
Read More
Arvinas discloses PROTAC compounds
Read More
Johns Hopkins University describes agents for the treatment of cancer
Read More
Newave Pharmaceutical develops FGFR4 inhibitors
Read More
Oncbiomune Pharmaceuticals enrolls patients for phase Ia study of Proscavax
Read More
University of Washington presents micro-dystrophins
Read More
Antibe Therapeutics completes phase II trial of ATB-346
Read More
Lycera begins enrollment in phase II trial of LYC-30937-EC in active ulcerative colitis
Read More
Armanezumab shows promise for AD
Read More
Immune mechanisms of the Mtb deltappe25-pe19 vaccine candidate
Read More
BioLineRx collaborates with MD Anderson Cancer Center for phase II study of BL-8040
Read More
Windtree receives grant to support Aerosurf phase IIb trial
Read More
Valeant licenses rights to develop and commercialize NER-1006 from Norgine
Read More
Alkermes submits sNDA to FDA for extended-release formulation of Aristada
Read More
Coherus BioSciences reports topline results for phase III study of CHS-1420
Read More
Selumetinib does not meet primary endpoint in phase III SELECT-1 trial
Read More
Proteostasis Therapeutics completes key preclinical milestone in collaboration with Astellas
Read More
Scintilla Pharmaceuticals acquires Scilex Pharmaceuticals to bolster pain management business
Read More
COMP grants orphan drug designation to AB Science's masitinib in ALS
Read More
FDA confirms sufficient data to advance E-2609 into phase III studies
Read More
